Alector's Q2 Net Loss Widens to $70.5M Amid R&D Spend

TL;DR

**ALEC is burning cash faster, but that's the game for a biotech; watch for clinical trial readouts, not just the bottom line.**

AI Summary

Alector, Inc. reported a net loss of $70.5 million for the quarter ended June 30, 2025, a significant increase from the $55.2 million net loss in the prior-year quarter. Revenue, primarily from collaboration agreements, was not explicitly detailed but operating expenses remained substantial. Research and development expenses were a major component of operating costs, reflecting the company's focus on its pipeline. The company's cash, cash equivalents, and marketable securities stood at $650.3 million as of June 30, 2025, down from $720.1 million at December 31, 2024, indicating a burn rate of approximately $69.8 million over six months. Strategic outlook remains tied to the progression of its clinical programs, particularly those in collaboration with GSK. The company continues to manage its liquidity to fund ongoing operations and clinical trials, with no new major financing activities reported in this quarter. The increase in net loss was primarily driven by higher operating expenses, including general and administrative costs, which rose to $20.1 million for the six months ended June 30, 2025, from $18.5 million in the prior year period.

Why It Matters

Alector's widening net loss to $70.5 million and a cash burn of nearly $70 million in six months signal increased operational costs, primarily in R&D, which is typical for a clinical-stage biotech. For investors, this highlights the long and expensive road to commercialization, requiring sustained capital. Employees face continued pressure to deliver clinical milestones to justify ongoing investment. Customers, primarily future patients, are awaiting successful drug development, while the broader market watches Alector's progress in the competitive neurodegenerative disease space, where breakthroughs could significantly shift market dynamics.

Risk Assessment

Risk Level: high — Alector's risk level is high due to its significant and increasing net loss of $70.5 million for Q2 2025, coupled with a substantial cash burn of $69.8 million in the first six months of 2025. The company's reliance on successful clinical trial outcomes and collaboration agreements, such as with GSK, for future revenue generation, without any approved products, presents inherent high-risk factors.

Analyst Insight

Investors should closely monitor Alector's clinical trial progress and upcoming data readouts, particularly for programs partnered with GSK, as these are the primary value drivers. Evaluate the cash burn rate against projected milestones; if the burn accelerates without significant clinical advancements, consider reducing exposure.

Financial Highlights

net Income

-$70.5M

cash Position

$650.3M

Key Numbers

• $70.5M — Net Loss (Increased from $55.2M in Q2 2024, indicating widening losses.)
• $650.3M — Cash, Cash Equivalents, and Marketable Securities (Decreased from $720.1M at year-end 2024, showing a $69.8M cash burn.)
• $20.1M — General and Administrative Expense (For six months ended June 30, 2025, up from $18.5M in prior year period.)
• 2025-06-30 — Period End Date (Current reporting period for the 10-Q filing.)
• 2025-08-07 — Filing Date (Date the 10-Q was filed with the SEC.)

Key Players & Entities

• Alector, Inc. (company) — filer of the 10-Q
• GSK (company) — collaboration partner
• Marc Grasso (person) — individual mentioned in trading plan
• Paula Hammond (person) — individual mentioned in stock awards
• $70.5 million (dollar_amount) — net loss for Q2 2025
• $55.2 million (dollar_amount) — net loss for Q2 2024
• $650.3 million (dollar_amount) — cash, cash equivalents, and marketable securities as of June 30, 2025
• $720.1 million (dollar_amount) — cash, cash equivalents, and marketable securities as of December 31, 2024
• $69.8 million (dollar_amount) — cash burn over six months
• $20.1 million (dollar_amount) — general and administrative expense for six months ended June 30, 2025

FAQ

Risk Factors

• Sustained Net Losses and Cash Burn [high — financial]: Alector reported a net loss of $70.5 million for the quarter ended June 30, 2025, an increase from $55.2 million in the prior year. The company's cash, cash equivalents, and marketable securities decreased to $650.3 million from $720.1 million at year-end 2024, indicating a burn rate of approximately $69.8 million over six months. This trend suggests a continued need for financing or a significant reduction in operating expenses to maintain solvency.
• High Research and Development Expenses [medium — operational]: Research and development expenses are a substantial component of Alector's operating costs, reflecting the company's investment in its pipeline. While necessary for innovation, these high costs contribute significantly to the net loss and require careful management to ensure efficient use of capital.
• Increasing General and Administrative Costs [medium — operational]: General and administrative expenses rose to $20.1 million for the six months ended June 30, 2025, from $18.5 million in the prior year period. This increase, while not as substantial as R&D, adds to the overall operating expense burden and warrants scrutiny for potential efficiencies.
• Dependence on Collaboration Agreements [medium — market]: Alector's revenue is primarily derived from collaboration agreements, notably with GSK. The success and financial performance of the company are therefore heavily reliant on the progress and outcomes of these partnerships, introducing concentration risk.

Industry Context

Alector operates in the highly competitive biotechnology sector, focusing on developing therapies for neurodegenerative diseases. This field is characterized by significant R&D investment, long development timelines, and high failure rates. Success often hinges on groundbreaking scientific innovation and strategic partnerships with larger pharmaceutical companies to fund and advance clinical programs.

Regulatory Implications

As a clinical-stage biotechnology company, Alector is subject to stringent regulatory oversight from bodies like the FDA. Delays in clinical trials, failure to meet efficacy endpoints, or issues with manufacturing can lead to significant setbacks and impact the company's ability to bring its therapies to market.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2025-06-30: Quarter End Date — Represents the end of the reporting period for the 10-Q filing, reflecting the company's financial position and performance.
• 2025-08-07: Filing Date — The date Alector, Inc. filed its Form 10-Q with the SEC, making the financial information publicly available.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance and condition. (This document provides the detailed financial information and disclosures for Alector, Inc. for the specified quarter.)

Collaboration Agreements

Contracts between two or more parties to work together on a project, often involving shared costs, risks, and rewards. In biotech, these typically involve drug development and commercialization. (Alector's primary source of revenue is from such agreements, making their terms and progress critical to the company's financial health.)

Cash Burn Rate

The rate at which a company is spending its available cash reserves, typically used for companies that are not yet profitable. (Understanding Alector's cash burn rate is crucial for assessing its liquidity and runway before it needs additional funding.)

Pipeline

The portfolio of drug candidates or therapeutic programs a pharmaceutical or biotechnology company is developing. (Alector's strategic focus and R&D expenses are directed towards advancing its pipeline, which is key to its future revenue potential.)

Year-Over-Year Comparison

Compared to the prior year quarter, Alector, Inc. has experienced a widening net loss, increasing from $55.2 million to $70.5 million. While revenue sources are not explicitly detailed, operating expenses, particularly general and administrative costs which rose to $20.1 million for the six months ended June 30, 2025, have increased. The company's cash position has also declined, indicating a higher cash burn rate, necessitating careful management of its financial resources.

From the Filing

0000950170-25-105050.txt : 20250807 0000950170-25-105050.hdr.sgml : 20250807 20250807161712 ACCESSION NUMBER: 0000950170-25-105050 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250807 DATE AS OF CHANGE: 20250807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alector, Inc. CENTRAL INDEX KEY: 0001653087 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 822933343 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38792 FILM NUMBER: 251194294 BUSINESS ADDRESS: STREET 1: 131 OYSTER POINT BLVD., SUITE 600 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-231-5660 MAIL ADDRESS: STREET 1: 131 OYSTER POINT BLVD., SUITE 600 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Alector LLC DATE OF NAME CHANGE: 20150915 10-Q 1 alec-20250630.htm 10-Q 10-Q false 280 364 Q2 --12-31 0001653087 http://fasb.org/srt/2025#ChiefExecutiveOfficerMember http://fasb.org/us-gaap/2025#OperatingExpenses 0001653087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001653087 us-gaap:CommonStockMember 2023-12-31 0001653087 2025-04-01 2025-06-30 0001653087 alec:GskMember 2022-01-01 2022-01-31 0001653087 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001653087 us-gaap:CommonStockMember 2024-06-30 0001653087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001653087 alec:MarcGrassoMember 2025-04-01 2025-06-30 0001653087 2024-12-31 0001653087 alec:CashEquivalentsAndMarketableSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001653087 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001653087 us-gaap:GeneralAndAdministrativeExpenseMember 2025-01-01 2025-06-30 0001653087 alec:GskMember srt:MaximumMember 2025-06-30 0001653087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001653087 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2025-06-30 0001653087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001653087 us-gaap:RetainedEarningsMember 2023-12-31 0001653087 alec:RestrictedStockAwardsAndRestrictedStockUnitsMember 2025-01-01 2025-06-30 0001653087 alec:MarcGrassoMember alec:Rule10B51TradingPlanMember 2025-06-30 0001653087 us-gaap:RetainedEarningsMember 2025-03-31 0001653087 2023-12-31 0001653087 2018-06-30 0001653087 us-gaap:CommonStockMember 2025-06-30 0001653087 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001653087 us-gaap:OverAllotmentOptionMember 2024-01-19 2024-01-19 0001653087 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001653087 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001653087 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001653087 alec:GskMember 2021-08-17 2021-08-17 0001653087 2025-01-01 2025-03-31 0001653087 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001653087 alec:GskMember 2024-12-31 0001653087 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-06-30 0001653087 us-gaap:CommonStockMember 2025-03-31 0001653087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001653087 alec:PaulaHammondMember 2025-04-01 2025-06-30 0001653087 alec:RestrictedStockAwardsAndRestrictedStockUnitsMember 2024-01-01 2024-06-30 0001653087 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001653087 2024-01-01 2024-03-31 0001653087 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001653087 alec:RestrictedStockAwardsAndRestrictedStockUnitsMember 2025-04-01 2025-06-30 0001653087 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001653087 alec:CertificateOfDepositMember us-gaap:FairValueInputs